University of California San Francisco
Give to UCSF
Last month new “bivalent” booster vaccines made by Moderna and Pfizer became available that protect against currently circulating Omicron variants as well as earlier strains of the SARS-CoV-2 virus that causes COVID-19. This Q&A features Joel Ernst, MD, a UCSF professor of medicine whose research aims to understand how pathogens evade the immune system.
On a sunny Friday, teams of aspiring young scientists gathered in the Clinical Sciences building at Parnassus Heights to look for treasure in a trillion data points about cancer.
A new therapy pulls forward a mutated version of the KRAS protein to help the immune system recognize and destroy cancer cells.
A UCSF study found that step counts, a measure of physical activity, were markedly lower early in the COVID-19 pandemic than pre-pandemic and remained lower on average in the two years following the onset of the global pandemic.
UCSF-led research outlines the comprehensive immune landscape and microbiome of pancreatic cysts as they progress from benign cysts to pancreatic cancer. Their findings could reveal the mechanism of neoplastic progression and provide targets for immunotherapy to inhibit progression or treat invasive disease.
Pregnant women in the U.S. are being exposed to chemicals like melamine, cyanuric acid, and aromatic amines that can increase the risk of cancer and harm child development, according to a study from researchers at UCSF and Johns Hopkins Bloomberg School of Public Health.
T cells used in immunotherapy treatments can get exhausted and shut down by fighting cancer cells and tumors. Using a CRISPR-based edit on these cells’ genomes, researchers at UCSF and Gladstone Institutes have rendered the therapeutic cells more resilient against tumors.
The repercussions of overturning Roe v. Wade – and the failure of the Supreme Court to provide any guidance on exceptions related to the life and health of the mother – are potentially catastrophic for women who face a life-threating diagnosis of pregnancy associated cancers (PAC).
UCSF researchers are part of a $200 million global consortium to develop new diagnostics, therapeutics, containment and control strategies to reduce the suffering from tuberculosis (TB) around the world.
A new UCSF study reports for the first time that significant hearing issues often occur among adult survivors of the most common forms of cancer.
